New drug combo aims to tame aggressive breast cancer

NCT ID NCT03377387

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a different dosing schedule of the chemotherapy drug capecitabine combined with the targeted therapy neratinib in people with advanced HER2-positive breast cancer. The goal is to find the safest dose that still works. About 34 adults with stage IV breast cancer that has spread will participate. The study is in early phases (1 and 2) to check safety and side effects first.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Baptist Alliance - McI

Miami, Florida, 33143, United States
Hartford Healthcare Cancer Institute @ Hartford Hospital

Hartford, Connecticut, 06102, United States
Lehigh Valley Health Network

Allentown, Pennsylvania, 18103, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge

Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.